GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SanBio Co Ltd (TSE:4592) » Definitions » Capex-to-Operating-Income

SanBio Co (TSE:4592) Capex-to-Operating-Income : 0.00 (As of Jan. 2024)


View and export this data going back to 2015. Start your Free Trial

What is SanBio Co Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

SanBio Co's Capital Expenditure for the three months ended in Jan. 2024 was 円0.00 Mil. Its Operating Income for the three months ended in Jan. 2024 was 円-814.45 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


SanBio Co Capex-to-Operating-Income Historical Data

The historical data trend for SanBio Co's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SanBio Co Capex-to-Operating-Income Chart

SanBio Co Annual Data
Trend Jan15 Jan16 Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23 Jan24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

SanBio Co Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of SanBio Co's Capex-to-Operating-Income

For the Biotechnology subindustry, SanBio Co's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SanBio Co's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SanBio Co's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where SanBio Co's Capex-to-Operating-Income falls into.



SanBio Co Capex-to-Operating-Income Calculation

SanBio Co's Capex-to-Operating-Income for the fiscal year that ended in Jan. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-54.969) / -4539.729
=N/A

SanBio Co's Capex-to-Operating-Income for the quarter that ended in Jan. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -814.454
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SanBio Co  (TSE:4592) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


SanBio Co Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of SanBio Co's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


SanBio Co (TSE:4592) Business Description

Traded in Other Exchanges
Address
8-1 Street Luke Tower 32nd Floor, Akashi-cho, Chuo-ku, Tokyo, JPN, 104-0044
SanBio Co Ltd is engaged in the research and development of regenerative cells drugs. The company has three types of drugs under development, including nerve regeneration cell SB623, used for the treatment of chronic cerebral infarction, traumatic brain injury, age-related macular degeneration, retinitis pigmentosa, Parkinson's disease, spinal cord injury and Alzheimer's disease; enhanced type-mesenchymal stem cells SB618, used to treat peripheral neuropathy, as well as muscle stem cells SB308, used in the treatment of muscular dystrophy.

SanBio Co (TSE:4592) Headlines

No Headlines